Combining Saphris and Seroquel: Safety Considerations
Combining Saphris (asenapine) and Seroquel (quetiapine) is generally not recommended as initial therapy, as there is limited evidence supporting the use of two antipsychotics from the same class, and both agents carry overlapping risks including QT prolongation, sedation, orthostatic hypotension, and metabolic effects.
Key Safety Concerns with This Combination
QT Prolongation Risk
Both medications prolong the QT interval, creating additive cardiac risk when combined:
- Saphris: Associated with QTc increases of 2-5 msec compared to placebo 1
- Quetiapine: Listed among antipsychotics that prolong QT interval 2
- Combined risk: The FDA label for Saphris explicitly states to "avoid in combination with other drugs known to prolong QTc including...antipsychotic medications (e.g., ziprasidone, chlorpromazine, thioridazine)" 1
Overlapping Adverse Effects
The combination amplifies shared side effects:
- Sedation: Both are sedating agents 3, 4
- Orthostatic hypotension: Both cause blood pressure drops, particularly problematic in elderly patients 1
- Falls risk: Additive somnolence and postural hypotension increase fall and fracture risk 1
- Metabolic effects: While asenapine is relatively weight-neutral, quetiapine can cause metabolic changes 5, 6
When Antipsychotic Polypharmacy Might Be Considered
If you are considering this combination, it should only be after documented failure of adequate monotherapy trials 7, 8. The 2009 AACAP guidelines state there is "limited evidence in children and adolescents for the use of two antipsychotics as an initial treatment approach or as a specific endpoint for treatment" 7.
Prerequisites Before Combining:
- Document failed monotherapy: Ensure adequate dose, duration, and confirmed adherence to at least one agent
- Clear clinical rationale: Identify specific target symptoms that justify the risk
- Monitoring plan: Establish baseline ECG, metabolic parameters, orthostatic vital signs
- Patient/family education: Discuss increased risks and obtain informed consent
Monitoring Requirements if Combination Used:
- Baseline ECG and repeat monitoring, especially if daily doses are high or other QT-prolonging drugs are present 1
- Orthostatic vital signs at each visit, particularly in elderly or cardiovascular disease patients 1
- Fall risk assessment and reassessment 1
- Metabolic monitoring: Weight, glucose, lipids
- Regular follow-up every few weeks initially to assess effectiveness 9
Common Pitfalls to Avoid
Do not use this combination to address psychosocial stressors or behavioral reactions that would be better managed with non-pharmacological interventions 7. The 2009 AACAP guidelines warn against "using medications to address 'all' of a patient's symptoms" when psychosocial interventions may be more appropriate 7.
Avoid in patients with:
- History of cardiac arrhythmias
- Congenital long QT syndrome
- Bradycardia, hypokalemia, or hypomagnesemia
- Concurrent use of other QT-prolonging medications 1
Drug Interaction Considerations
Quetiapine has significant drug interactions that could affect this combination:
- Carbamazepine reduces quetiapine levels by 86% (factor of 10 reduction) 10, 11
- Fluvoxamine increases quetiapine levels by 159% 10
- Clozapine increases quetiapine levels by 82% 10
Alternative Approach
Consider sequential monotherapy optimization before polypharmacy 8. If one antipsychotic is partially effective, try:
- Optimizing the dose (confirm with therapeutic drug monitoring if available)
- Ensuring adequate treatment duration (typically 4-6 weeks at therapeutic dose)
- Switching to a different antipsychotic rather than adding a second one
- Adding a mood stabilizer or other augmentation strategy rather than a second antipsychotic
If antipsychotic polypharmacy is already in place and the patient is stable, consider attempting a gradual taper back to monotherapy, as many patients can tolerate this successfully 8.